Search results
Results from the WOW.Com Content Network
Olmesartan, sold under the brand name Benicar among others, is a medication used to treat high blood pressure (hypertension). [ 1 ] [ 2 ] It is taken orally (swallowed by mouth). [ 2 ] Versions are available as the combination olmesartan/hydrochlorothiazide and olmesartan/amlodipine . [ 2 ]
In the United States, the JNC8 (Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommends thiazide-type diuretics to be one of the first-line drug treatments for hypertension, either as monotherapy or in combination with calcium channel blockers, ACEis, or ARBs. [7]
The treatment of moderately high arterial blood pressure (defined as >160/100 mmHg) with medications is associated with an improved life expectancy. [15] The effect of treatment of blood pressure between 130/80 mmHg and 160/100 mmHg is less clear, with some reviews finding benefit [6] [16] [17] and others finding unclear benefit.
In cats, it is the first line of treatment due to its efficacy and few side effects. [63] Systemic hypertension in cats is usually secondary to another abnormality, such as chronic kidney disease , and so amlodipine is most often administered to cats with kidney disease . [ 64 ]
In a systematic review, the DASH diet reduced blood pressure by an average of 5.2/2.6 mmHg, however the blood pressure lowering effects may vary and will typically have a greater effect in people with a higher baseline blood pressure (especially those with hypertension) or BMI. [22] The review found the DASH diet to reduce total cholesterol ...
Guidelines on the choice of agents and how best to step up treatment for various subgroups in hypertension (high blood pressure) have changed over time and differ between countries. A Comparison of International Guidelines on Goal Blood Pressure and Initial Therapy for Adults With Hypertension (adapted from JNC 8 guidelines [ 1 ] )
Aprocitentan was approved for medical use in the United States in March 2024. [1]In April 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Jeraygo, intended for the treatment of resistant hypertension in adults.
Although severe hypertension is more common in the elderly, it may occur in children (though very rarely), likely due to metabolic or hormonal dysfunction. In 2014, a systematic review identified women as having slightly higher increased risks of developing hypertensive crises than do men. [5]